Press Releases

Date Title and Summary Additional Formats
Toggle Summary Evoke Pharma Reports Third Quarter 2020 Financial Results
Gimoti™ commercial launch underway SOLANA BEACH, Calif. , Nov. 10, 2020 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced its financial results for the third quarter ended September 30,
View HTML
Toggle Summary Evoke and EVERSANA Announce Commercial Launch of Gimoti™
Product launch provides healthcare providers a novel treatment approach for patients suffering from symptoms of acute and recurrent diabetic gastroparesis SOLANA BEACH, Calif. and CHICAGO , Oct. 26, 2020 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company
View HTML
Toggle Summary Evoke Pharma to Participate in the H.C. Wainwright 22nd Annual Global Investment Conference
SOLANA BEACH, Calif. , Sept. 09, 2020 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that Dave Gonyer R .Ph., President and Chief Executive Officer, and Matt D’Onofrio, Chief
View HTML
Toggle Summary Evoke Pharma and EVERSANA Announce the Appointment of Christopher Quesenberry as Chief Commercial Officer for Gimoti™
Gimoti commercial launch on track for the fourth quarter of 2020 SOLANA BEACH, Calif. and CHICAGO , Aug. 25, 2020 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases and EVERSANA™, a leading provider of
View HTML
Toggle Summary Evoke Pharma Reports Second Quarter 2020 Financial Results
Preparing for commercial launch of GIMOTI™ in 4Q 2020 SOLANA BEACH, Calif. , Aug. 06, 2020 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced its financial results for the second quarter
View HTML
Toggle Summary Evoke Pharma Initiates Commercial Manufacturing of Gimoti™
Preparing commercial launch of GIMOTI™ in 4Q 2020 SOLANA BEACH, Calif. , July 15, 2020 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that it has initiated the commercial
View HTML
Toggle Summary Evoke Pharma Extends Cash Runway to 2Q 2021
Preparing to initiate commercial sales of GIMOTI™ in 4Q 2020 SOLANA BEACH, Calif. , July 08, 2020 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that as of June 30, 2020 it had cash
View HTML
Toggle Summary FDA Approves Evoke’s GIMOTI™
Commercial Partner EVERSANA Prepares for GIMOTI Launch Evoke Extends Cash Runway into 2021 SOLANA BEACH, Calif. , June 19, 2020 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that
View HTML
Toggle Summary Evoke Receives FDA Conditional Acceptance of Gimoti Brand Name Following NDA Resubmission
SOLANA BEACH, Calif. , May 20, 2020 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that the U.S. Food and Drug Administration (FDA) has conditionally accepted the proprietary brand
View HTML
Toggle Summary Evoke Pharma Reports First Quarter 2020 Financial Results and Changes its 2020 Annual Meeting of Stockholders to a Virtual Format
Gimoti™ Prescription Drug User Fee Act (PDUFA) date is June 19, 2020 SOLANA BEACH, Calif. , May 12, 2020 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced its financial results for the
View HTML